Visits to the Stead Center are by appointment only. Please call the NCAPA office for more information. Read More »

Visits to the Stead Center are by appointment only. Please call the NCAPA office for more information. Read More »

Events

  • AHRQ Stroke Prevention in Atrial Fibrillation Webinar

    Starts: June 17, 2014 - 1:00 pm

    Ends: June 17, 2014 - 2:00 pm



    Organizer: AHRQ Effective Health Care Program - EHC_Outreach@ahrq.hhs.gov

    Website: http://www.ahrq.gov/


    Cost: Free


    The Webinar will highlight findings from the AHRQ research review Stroke Prevention in Atrial Fibrillation, as well as provide an overview of AHRQ’s Effective Health Care (EHC) Program and CVD resources from the Million Hearts® initiative. Attendees will learn about key findings from the AHRQ report and have an opportunity to engage with leaders from AHRQ, Million Hearts®, and the ACC. Speakers

    • Sana M. Al-Khatib, M.D., M.H.S., associate professor of medicine, Duke Clinical Research Institute, Duke University Medical Center
    • Tahleah R. Chappel, M.S., coordinator, community outreach and engagement, Center for Outcomes and Evidence, AHRQ
    • Howard Holland, director, Office of Communications and Knowledge Transfer, AHRQ
    • Mary Norine Walsh, M.D., F.A.C.C., chair, American College of Cardiology, Patient-Centered Care Committee, and medical director, Heart Failure and Transplantation, St. Vincent Heart Center of Indiana
    • Janet Wright, M.D., F.A.C.C., executive director, Million Hearts®

    Participants will—

    1. Understand the goals of AHRQ’s EHC Program, the National Partnership Network, and the Million Hearts® initiative and how to get involved.
    2. Identify resources from AHRQ’s EHC Program and Million Hearts® that can be used for clinician education and patient engagement.
    3. Understand underutilized risk stratification tools (CHADS2, CHA2DS2-VASc, and HAS-BLED) and identify which tools work best for determining the risk level of stroke events and which work best for determining the risk level of bleeding events.
    4. Assess which new oral anticoagulants are able to reduce the risk of both stroke and bleeding events when compared to traditional therapies used in patients with non-rheumatic atrial fibrillation.

    REGISTER HERE

  • Back to Events